Frontlight ResearchEarly access
CompletedNo phase
SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation
Key facts
- Who runs it
- Edwards Lifesciences
- Where
- Atlanta, Detroit, Evanston, Los Angeles, Murray, Norfolk, Rochester, and San Francisco, United StatesSee the 8 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Completed
- People taking part
- 72 people enrolled
- Started
- 14 Sept 2017
- Ended
- 20 Aug 2026
- Type of study
- Interventional
- Treatments tested
- Edwards SAPIEN M3 System
- Record updated
- 25 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- 18 years of age or older
- MR ≥ 3+
- NYHA functional class ≥ II
- High risk of cardiovascular surgery
- Hemodynamically stable while on heart failure medication for at least 2 weeks before the procedure
- The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent
Who cannot take part
- Prior surgical or interventional treatment of mitral valve preventing appropriate device access and deployment
- Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days
- Inability to tolerate or a medical condition precluding treatment with anti-thrombotic therapy
- Patients with renal insufficiency or receiving renal replacement therapy
- Participating in another investigational drug or device study
- Cardiac imaging evidence of intracardiac mass, thrombus or vegetation
- History of cardiac transplantation
- History of recurrent and/or unprovoked deep vein thrombosis or pulmonary embolism
- Clinically significant untreated coronary artery disease requiring revascularization
- Stroke or transient ischemic attack within 90 days of the procedure
- Myocardial infarction within 30 days of the procedure
- Leukopenia, anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy, or hypercoagulable states
- Irreversible, severe pulmonary hypertension
- Liver disease or significantly abnormal liver function test results
- LV Ejection Fraction <30%
- Mitral anatomy that would preclude appropriate delivery and deployment of the dock or valve
- Significant risk of LVOT obstruction
- Severe right ventricular dysfunction
- Patient is inoperable
- Need for aortic, tricuspid or pulmonic valve replacement
- Presence of mechanical aortic valve prosthesis
- Active bacterial endocarditis within 180 days of the procedure
- Hospitalization for CHF or hemodynamic instability requiring inotropic support or intra-aortic balloon pump within 30 days
- Refusal of blood products
- Female who is pregnant or lactating
- Estimated life expectancy < 12 months
Where in United States
Also in 1 other country, 1 site
- Emory UniversityAtlanta, United States
- Henry Ford HospitalDetroit, United States
- Evanston/ Northshore UniversityEvanston, United States
- Cedars-Sinai Medical Center Heart InstituteLos Angeles, United States
- Intermountain Medical CenterMurray, United States
- Sentara Cardiovascular Research InstitutionNorfolk, United States
- Mayo ClinicRochester, United States
- California Pacific Medical CenterSan Francisco, United States
About the trial
What the trial wants to find out
This study will evaluate the safety and functionality of the SAPIEN M3 System in patients with symptomatic, severe MR and will provide guidance for future clinical study designs utilizing the SAPIEN M3 System.
The group in the trial
- TMVRTreatment being tested
Subjects will undergo transcatheter mitral valve replacement
Treatment: Edwards SAPIEN M3 System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation
- Record updated
- 25 September 2026